The DOI matches its Crossref record; 41 of the 43 references it cites were found in a registry or an index; 11 of the 22 sources its claims cite were checked for support.
Trial-based economic evaluation of the BrainACT study: acceptance and commitment therapy for anxiety and/or depressive symptoms after acquired brain injury.
Open accessAbstract
INTRODUCTION: Following acquired brain injury (ABI), individuals often experience anxiety and/or depressive symptoms. BrainACT is an adapted form of Acceptance and Commitment Therapy (ACT) tailored to this target group. The current study is a trial-based health-economic evaluation comparing BrainACT to a psychoeducation and relaxation control treatment. METHODS: An economic evaluation from a societal perspective was conducted in the Netherlands alongside a multicenter randomized controlled two-armed parallel trial including 72 participants. A cost-utility and cost-effectiveness analysis was conducted where incremental costs, quality-adjusted life-years (QALYs), and anxiety/depression (Hospital Anxiety and Depression Scale (HADS) score) were collected and presented over a 1-year follow-up period. Bootstrapping, scenario, and subgroup analyses were performed to test the robustness of the results. RESULTS: The BrainACT arm reported non-significant lower total costs (incremental difference of €-4,881; bootstrap interval €-12,139 to €2,330) combined with significantly decreased anxiety/depression (HADS) (3.2; bootstrap intervals 0.7-5.7). However, the total QALYs were non-significantly lower (-0.008; bootstrap interval -0.060 to 0.042) for BrainACT. The probability of the intervention being cost-effective was 86 percent at a willingness-to-accept threshold of €50,000/QALY. The scenario and subgroup analyses confirmed the robustness of the results. CONCLUSION: BrainACT may be a more cost-effective alternative to a psychoeducation and relaxation intervention for anxiety and/or depressive symptoms following ABI. Despite limitations, BrainACT appears to be a promising addition to treatment options in the Netherlands. Further research is needed to validate these findings, and consideration should be given to implementing BrainACT in Dutch clinical settings with ongoing monitoring.
Overview
CoChat Summary
## TL;DR
This trial-based economic evaluation found that BrainACT, an adapted ACT program for people with anxiety and/or depressive symptoms after acquired brain injury, was likely more cost-effective than psychoeducation plus relaxation from a societal perspective over 1 year. It produced lower mean costs and significantly better HADS outcomes, but slightly lower QALYs.
## Key findings
- In the base-case societal analysis, BrainACT had lower mean total costs by €4,881 (bootstrap interval €−12,139 to €2,330) and better anxiety/depression outcomes by 3.2 HADS points (bootstrap interval 0.7–5.7).
- BrainACT had non-significantly lower QALYs of −0.008 (bootstrap interval −0.060 to 0.042).
- The probability that BrainACT was cost-effective was 86% at a willingness-to-accept threshold of €50,000/QALY.
- In outcome testing over 12 months, the active control arm had significantly higher HADS depression scores (p = 0.013) and HADS total scores (p = 0.031), while QALYs (p = 0.775) and HADS anxiety (p = 0.372) did not differ significantly.
## Methods
- Conducted alongside a multicenter randomized controlled two-armed parallel trial in the Netherlands, using a societal perspective and a 1-year follow-up.
- Included 72 participants with objectified TBI or stroke and anxiety/depressive symptoms; 36 were randomized to BrainACT and 36 to psychoeducation plus relaxation.
- Main analyses used intention-to-treat, mixed models for incremental outcomes, and 1,000 bootstrap replications; missing data were addressed with multiple imputation.
## Limitations
- The paper states the sample size was 72, below the target of 94, which may have reduced statistical power and made subgroup analyses harder to interpret.
- It reports inconsistencies in productivity data and notes these were handled by truncation; the text says results were still robust when inconsistent records were excluded.
- Follow-up was only 1 year, which the authors say may be too short to assess long-term cost-effectiveness.
- The paper also notes that material and facility costs were not included in intervention costs due to limited database information; this is an evident limitation from the text.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
3 Valid · 6 Not valid · 4 Not checked · 53 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Although treating these symptoms remains a challenge, evidence suggests that Acceptance and Commitment Therapy (ACT) can be an effective treatment for ABI-related anxiety and depressive symptoms (10–13).”
§ Trial-based economic evaluation of the BrainACT study: acceptance and commitment therapy for anxiety and/or depressive symptoms after acquired brain injury > Introduction
What the sources say
- Not checked — no full text of the sourcecites [10] source
- Could not verifycites [11] sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) addresses the prevalence and comorbidity of anxiety and depression after stroke, not the effectiveness of ACT. Searches for “Acceptance and Commitment Therapy,” “ACT,” and “effective treatment” found no passage in our copy assessing ACT for ABI-related symptoms. (LLM, conf=0.76)
- Supportedcites [12] source
The Introduction says there is some evidence that people with depressive or anxiety symptoms after ABI can benefit from ACT. It reports a trial showing reduced depression and a case study showing reduced anxiety and depressive symptoms. The Discussion characterizes these earlier findings as promising while noting that no large RCT had established effectiveness. (LLM, conf=0.88)
- Could not verifycites [13] sourceExperimental — accuracy not yet measured
The retrieved CHEERS passages discuss reporting health economic evaluations and examples of cost-effectiveness analyses; they do not address ACT as a treatment for acquired brain injury. Searches for Acceptance and Commitment Therapy, ABI, anxiety, and depressive symptoms found no passage supporting the attributed claim. Page numbers were unavailable in our copy. (LLM, conf=0.76)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“and analysis adherence to the Dutch economic evaluations guidelines (25).”
§ Trial-based economic evaluation of the BrainACT study: acceptance and commitment therapy for anxiety and/or depressive symptoms after acquired brain injury > Discussion > Strength and limitations
What the sources say
- Could not verifycites [25] sourceExperimental — accuracy not yet measured
The Data analysis section describes repeated-measures ANOVA and intention-to-treat analysis but does not mention Dutch economic evaluation guidelines. The Methods Design section says the trial was reported according to CONSORT; searches for the Dutch guidelines and economic evaluation found no passage addressing the claimed adherence. Page numbers were not available in our copy. (LLM, conf=0.76)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The results were sensitive to the method of valuing productivity.”
§ Trial-based economic evaluation of the BrainACT study: acceptance and commitment therapy for anxiety and/or depressive symptoms after acquired brain injury > Discussion
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The outcomes for SGA3 (working vs. not working) remained robust.”
§ Trial-based economic evaluation of the BrainACT study: acceptance and commitment therapy for anxiety and/or depressive symptoms after acquired brain injury > Results > Scenario and subgroup analyses results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This resulted in a higher cost-effectiveness probability for participants under 60 years old (89 percent vs. 50 percent).”
§ Trial-based economic evaluation of the BrainACT study: acceptance and commitment therapy for anxiety and/or depressive symptoms after acquired brain injury > Results > Scenario and subgroup analyses results
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
23 more claims
Create a free account to see all 66 claims and every source verdict.
- It may state two separate claims as one. 27
- Probably not a substantial claim. 16
Citations
Cites
The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139
Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)
Herdman, M., Gudex, C., Lloyd, A., Janssen, M., Kind, P., Parkin, D., Bonsel, G., & Badia, X. (2011) · Quality of Life Research · doi:10.1007/s11136-011-9903-x · Cited by 9,795
The validity of the Hospital Anxiety and Depression Scale
Bjelland, I., Dahl, A. A., Haug, T. T., & Neckelmann, D. (2002) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(01)00296-3 · Cited by 9,779
Acceptance and commitment therapy: model, processes and outcomes
Hayes, S. C., Luoma, J. B., Bond, F. W., Masuda, A., & Lillis, J. (2006) · Behaviour Research and Therapy · doi:10.1016/j.brat.2005.06.006 · Cited by 6,587
Valuing health-related quality of life: an EQ-5D-5L value set for England
Devlin, N. J., Shah, K. K., Feng, Y., Mulhern, B., & van Hout, B. (2018) · Health Economics · doi:10.1002/hec.3564 · Cited by 1,356
A-Tjak, J. G. L., Davis, M. L., Morina, N., Powers, M. B., Smits, J. A. J., & Emmelkamp, P. M. G. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000365764 · Cited by 1,031
Husereau, D., Drummond, M., Augustovski, F., de Bekker-Grob, E., Briggs, A. H., Carswell, C., Caulley, L., Chaiyakunapruk, N., Greenberg, D., Loder, E., et al. (2022) · Value in Health · doi:10.1016/j.jval.2021.10.008 · Cited by 847
Faria, R., Gomes, M., Epstein, D., & White, I. R. (2014) · PharmacoEconomics · doi:10.1007/s40273-014-0193-3 · Cited by 673
The empirical status of acceptance and commitment therapy: A review of meta-analyses
Gloster, A. T., Walder, N., Levin, M. E., Twohig, M. P., & Karekla, M. (2020) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2020.09.009 · Cited by 622
Acceptance and commitment therapy: A meta-analytic review
Powers, M. B., Zum Vörde Sive Vörding, M. B., & Emmelkamp, P. M. G. (2009) · Psychotherapy and Psychosomatics · doi:10.1159/000190790 · Cited by 619
Research works printed but not linked: 2
- Hakkaart, 2016, Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg
- Zwaap, 2015, Kosteneffectiviteit in de praktijk [Dutch]
Metadata
- Authors
- Osstyn, S., Rauwenhoff, J., Handels, R., de Vugt, M. E., Evers, S., van Mastrigt, G. A. P. G., & van Heugten, C. M.
- Affiliations
- Maastricht University (NL)
- Norwegian University of Science and Technology (NO)
- Venue
- International Journal of Technology Assessment in Health Care
- Publisher
- Cambridge University Press (CUP)
- Published
- 2025
- Volume
- 41
- Issue
- 1
- Pages
- e10-e10
- ISSN
- 0266-4623 (ISSN-L)
- 1471-6348
- PMC
- PMC11811953
- OpenAlex
- W4407291766
- Cited by
- 0
- References
- 43
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Technology Assessment in Health Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, cc-by-nc-nd)
- Funders
- ZonMw (636310003)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Social Sciences › Psychology › Clinical Psychology › Mindfulness and Compassion Interventions
- Health Sciences › Medicine › Clinical Neurology › Traumatic Brain Injury Research
- Keywords
- acceptance and commitment therapy, acquired brain injury, anxiety, depressive symptoms, cost-effectiveness, cost-utility analysis, psychoeducation, relaxation training, quality-adjusted life years
- MeSH terms
- Adult, Anxiety, Brain Injuries, Cost-Benefit Analysis, Depression, Female, Humans, Male, Middle Aged, Netherlands, Quality-Adjusted Life Years, Acceptance and Commitment Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Trial-based economic evaluation of the BrainACT study: acceptance and commitment therapy for anxiety and/or depressive symptoms after acquired brain injury. https://app.cochat.ai/papers/10.1017/s0266462324004811
- The paper
- Osstyn, S., Rauwenhoff, J., Handels, R., de Vugt, M. E., Evers, S., van Mastrigt, G. A. P. G., & van Heugten, C. M. (2025). Trial-based economic evaluation of the BrainACT study: acceptance and commitment therapy for anxiety and/or depressive symptoms after acquired brain injury. International Journal of Technology Assessment in Health Care. https://doi.org/10.1017/s0266462324004811
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
